A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer
|ClinicalTrials.gov Identifier: NCT01237171|
Recruitment Status : Unknown
Verified November 2010 by IsoRay Medical, Inc..
Recruitment status was: Recruiting
First Posted : November 9, 2010
Last Update Posted : November 9, 2010
|Condition or disease||Intervention/treatment|
|NSCLC Non Small Cell Lung Cancer||Radiation: Cesium-131 Brachytherapy Seed|
|Study Type :||Observational|
|Estimated Enrollment :||40 participants|
|Official Title:||Outcome Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage NSCLC|
|Study Start Date :||November 2010|
|Estimated Primary Completion Date :||May 2014|
|Estimated Study Completion Date :||May 2014|
Sub-lobar resection with Cesium-131
All enrolled patients will undergo sub-lobar resection and brachytherapy implant with Cesium-131 in an effort to study and quantify recurrence/control patterns.
Radiation: Cesium-131 Brachytherapy Seed
85 Gray Dose
Other Name: Sealed Brachytherapy Source CS-1 (IsoRay Medical)
- Local Recurrence [ Time Frame: 3 Years ]Cancer regrowth in the area where it was surgically removed
- Quality of Life [ Time Frame: 2 years ]Using questionnaires, data will be collected related to the sense of well-being experienced by the patient after treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01237171
|United States, New York|
|Weill Cornell Medical College||Recruiting|
|New York, New York, United States, 10021|
|Contact: Bhupesh Parashar, M.D. 212-746-3612 email@example.com|
|Contact: Mei-Ki Chan, M.A. 212-746-9297 firstname.lastname@example.org|
|Principal Investigator: Bhupesh Parashar, M.D.|
|Principal Investigator:||Bhupesh Parashar, M.D.||Weill Medical College of Cornell University|